Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
Fudala PJ; Bridge TP; Herbert S; Williford WO; Chiang CN; Jones K; Collins J; Raisch D; Casadonte P; Goldsmith RJ; Ling W; Malkerneker U; McNicholas L; Renner J; Stine S; Tusel D; The New England Journal Of Medicine, 2003, vol. 349, issue 10, p 949, ISSN 15334406. ISBN 15334406.
Full Text Resources Located for this Citation